Mysona D, et al. - A sum of 71 females at Augusta University diagnosed with ovarian cancer were analyzed between 2005 and 2015 to assess the efficacy of a combined panel of protein biomarkers and clinical factors to predict the recurrence in serous ovarian cancer cases by using the SOMAscan array to measure the levels of 1129 proteins. They observed Brain-Derived Neurotrophic Factor and Platelet Derived Growth Factor molecules vital to prognosticate progression-free survival (PFS). They found the serous high-grade ovarian cancer (SHOC) score model helpful in early intervention and consolidation therapy policies in remission cases intended to recur.